1. Home
  2. MATH vs INMB Comparison

MATH vs INMB Comparison

Compare MATH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$1.06

Market Cap

46.0M

Sector

Finance

ML Signal

HOLD

Logo INmune Bio Inc.

INMB

INmune Bio Inc.

HOLD

Current Price

$1.28

Market Cap

37.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
INMB
Founded
2015
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.0M
37.2M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
MATH
INMB
Price
$1.06
$1.28
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.40
AVG Volume (30 Days)
99.2K
275.8K
Earning Date
05-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.85
EPS
N/A
N/A
Revenue
N/A
$50,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
N/A
Revenue Growth
N/A
257.14
52 Week Low
$0.84
$1.09
52 Week High
$4.10
$11.64

Technical Indicators

Market Signals
Indicator
MATH
INMB
Relative Strength Index (RSI) 53.90 45.98
Support Level $1.05 $1.15
Resistance Level $1.16 $1.52
Average True Range (ATR) 0.11 0.09
MACD 0.02 -0.01
Stochastic Oscillator 70.50 29.85

Price Performance

Historical Comparison
MATH
INMB

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About INMB INmune Bio Inc.

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Share on Social Networks: